Perceptions among the U.S. population of value of Japanese encephalitis (JE) vaccination for travel to JE-endemic countries.

Autor: Hills SL; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA. Electronic address: shills@cdc.gov., Fischer M; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA., Biggerstaff BJ; Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2020 Feb 24; Vol. 38 (9), pp. 2117-2121. Date of Electronic Publication: 2020 Jan 25.
DOI: 10.1016/j.vaccine.2020.01.048
Abstrakt: Introduction: Japanese encephalitis (JE) is a rare but potentially severe disease among travelers. JE vaccine in the United States costs $500-$600 for a 2-dose series and is safe and effective but rare serious adverse events can occur. Our survey investigated likelihood of vaccine receipt for travel.
Methods: An electronically-administered survey was conducted among U.S. adults. Participants were presented a hypothetical scenario on travel to a JE-endemic country and JE vaccine characteristics and responded on likelihood of vaccination.
Results: Overall, 6384 (59%) of 10,904 persons completed the questions. Population estimates indicated 32% would be likely and 42% were unlikely to be vaccinated, and 26% were unsure. Among those likely to get vaccinated, important factors were disease risk and severity, and vaccine safety. Among those unlikely, cost, disease risk, and possibility of serious side effects ranked highest.
Conclusions: There is population heterogeneity in perception of JE disease risk and value of vaccination.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: